SLC7A11
Cystine/glutamate transporter
Protein Summary
Sodium-independent, high-affinity exchange of anionic amino acids with high specificity for anionic form of cystine and glutamate. This gene encodes a member of a heteromeric, sodium-independent, anionic amino acid transport system that is highly specific for cysteine and glutamate. In this system, designated Xc(-), the anionic form of cysteine is transported in exchange for glutamate. This protein has been identified as the predominant mediator of Kaposi sarcoma-associated herpesvirus fusion and entry permissiveness into cells. Also, increased expression of this gene in primary gliomas (compared to normal brain tissue) was associated with increased glutamate secretion via the XCT channels, resulting in neuronal cell death. [provided by RefSeq, Sep 2011]
- ENST00000280612
- ENSP00000280612
- ENSG00000151012
- xCT
- CCBR1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
gene perturbation | 1 | ||
small molecule perturbation | 1 | ||
microRNA | 0.92 | ||
molecular function | 0.91 | ||
transcription factor perturbation | 0.8 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 706.83 (req: < 5)
Gene RIFs: 151 (req: <= 3)
Antibodies: 301 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 706.83 (req: >= 5)
Gene RIFs: 151 (req: > 3)
Antibodies: 301 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 31
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 13
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 1